Sun Pharma introduces Brivaracetam dosage forms at affordable price for epilepsy treatment
Sun Pharmaceutical Industries Limited today announced that the company will introduce the complete range of Brivaracetam dosage forms at an affordable price for epilepsy treatment in India.
Reacting to this, the company’s stock today increased by 2.09 per cent and made an intraday high of Rs 608.20 per share at 1.15 pm.
Besides, the company reported a net profit of Rs 1,918.11 crore in Q3FY21, an increase of 87.37 per cent. It had reported a profit of Rs 1,023.71 crore in Q3FY20. The company reported net sales of Rs 8,781.84 crore for Q3FY21, an increase of 9.25 per cent as against the net sales of Rs 8,038.65 crore for Q3FY20.
Sun Pharma is a speciality generic pharmaceutical company. It is India's top pharmaceutical company and delivers high-quality products in over 100 countries across the world at affordable prices.
According to BSE data, the stock traded at a P/E multiple of 48.16 and a price-to-book ratio of 5.61. The stock has a 52-week high and a 52-week low of Rs 653.70 and Rs 315.20, respectively.
At 2.24 pm today, the stock of the company was trading at Rs 604.70, up by 1.50 per cent on BSE.